{"id":60763,"date":"2024-02-28T07:07:04","date_gmt":"2024-02-28T07:07:04","guid":{"rendered":"https:\/\/medsname.com\/teravir\/"},"modified":"2026-05-08T09:18:45","modified_gmt":"2026-05-08T09:18:45","slug":"teravir","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/teravir\/","title":{"rendered":"Teravir"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:16px 20px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin-top:0;\">Quick Answer &mdash; Teravir (Tenofovir Disoproxil 300 mg)<\/h3>\n<ul>\n<li><strong>Substan\u021b\u0103 activ\u0103:<\/strong> tenofovir disoproxil fumarat (TDF) 300 mg, comprimat oral, luat o dat\u0103 pe zi cu m\u00e2ncare.<\/li>\n<li><strong>Indica\u021bie principal\u0103 \u00een aceast\u0103 list\u0103:<\/strong> infec\u021bie cronic\u0103 cu virusul hepatitei B (HBV) la adul\u021bi \u2014 suprimare pe termen lung a replic\u0103rii virale. Utilizat \u0219i \u00een regimurile HIV, dar niciodat\u0103 ca monoterapie HIV (risc de rezisten\u021b\u0103).<\/li>\n<li><strong>Mecanism:<\/strong> inhibitor nucleotidic al transcriptazei inverse (NRTI). Tenofovir-difosfatul concureaz\u0103 cu dATP-ul natural, este \u00eencorporat \u00een lan\u021bul de ADN viral \u0219i \u00eel termin\u0103.<\/li>\n<li><strong>Eficacitate HBV:<\/strong> &gt; 90% ating ADN HBV nedetectabil la 5 ani; rezisten\u021b\u0103 &lt; 1% peste 8+ ani \u2014 cea mai mare barier\u0103 la rezisten\u021b\u0103 dintre toate agen\u021bii orali pentru HBV.<\/li>\n<li><strong>Monitorizare important\u0103 a siguran\u021bei:<\/strong> func\u021bia renal\u0103 (eGFR), fosfatul seric \u0219i densitatea mineral\u0103 osoas\u0103 \u2014 verifica\u021bi \u00eenainte de tratament, apoi la fiecare 3\u20136 luni. Dac\u0103 CrCl scade sub 50 mL\/min, este necesar\u0103 ajustarea intervalului de dozare.<\/li>\n<li><strong>Avertizare reactivare HBV:<\/strong> \u00eentreruperea brusc\u0103 a tenofovirului \u00een hepatita B cronic\u0103 poate declan\u0219a reactiv\u0103ri hepatice acute severe \u2014 nu \u00eentrerupe\u021bi f\u0103r\u0103 supraveghere specializat\u0103.<\/li>\n<\/ul>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">What Is Teravir?<\/h2>\n<p>Teravir is an oral tablet containing <strong>tenofovir disoproxil fumarat 300 mg<\/strong> (TDF), fabricat de Cipla. Fiecare ambalaj con\u021bine \u00een mod obi\u0219nuit 30 de comprimate filmate.<\/p>\n<p>Tenofovir este un <strong>inhibitor nucleotidic al transcriptazei inverse<\/strong> (NtRTI) utilizat pentru dou\u0103 indica\u021bii virale cronice distincte \u2014 hepatita B cronic\u0103 (HBV) \u0219i HIV-1 \u2014 ambele folosind o transcriptaz\u0103 invers\u0103 viral\u0103 pentru a-\u0219i copia genomul. Aceea\u0219i molecul\u0103 este v\u00e2ndut\u0103 sub marca original\u0103 <strong>Viread<\/strong> (Gilead, aprobat \u00een 2001 pentru HIV, \u00een 2008 pentru HBV).<\/p>\n<h2 class=\"wp-block-heading\">What Is Teravir Used For?<\/h2>\n<ul>\n<li><strong>Hepatit\u0103 B cronic\u0103 (HBC) la adul\u021bi \u0219i adolescen\u021bi \u2265 12 ani<\/strong> \u2014 antiviral oral de prim\u0103 linie pentru infec\u021bia cronic\u0103 HBeAg-pozitiv\u0103 \u0219i HBeAg-negativ\u0103 (conform ghidurilor EASL, AASLD, APASL, WHO).<\/li>\n<li><strong>infec\u021bia cu HIV-1<\/strong> \u2014 doar ca parte a unui regim de combina\u021bie, de obicei cu emtricitabin\u0103 (FTC) sau lamivudin\u0103 (3TC) plus un al treilea agent (inhibitor de integraz\u0103 sau NNRTI). Niciodat\u0103 ca monoterapie pentru HIV.<\/li>\n<li><strong>Profilaxia pre-expunere la HIV (PrEP)<\/strong> \u2014 de obicei sub forma combina\u021biei cu doz\u0103 fix\u0103 TDF + FTC (Truvada \/ Tenvir-EM); TDF ca agent unic pentru PrEP este sus\u021binut de unele ghiduri pentru expunerea heterosexual\u0103 cisgender, dar nu este de prim\u0103 linie.<\/li>\n<li><strong>Profilaxia post-expunere la HIV (PEP)<\/strong> \u2014 component\u0103 a regimului standard de 28 de zile cu trei medicamente.<\/li>\n<\/ul>\n<p>Tenofovir este <strong>prime\u0219te,<\/strong> activ \u00eempotriva hepatitei C, herpes simplex sau gripei sezoniere \u2014 este selectiv pentru transcriptazele inverse ale HIV \u0219i HBV.<\/p>\n<h2 class=\"wp-block-heading\">How Does Teravir Work?<\/h2>\n<p>Tenofovir disoproxil este un <strong>prodrog<\/strong>: dup\u0103 absorb\u021bie este hidrolizat la tenofovir, apoi fosforilat intracelular la tenofovir-difosfat (TFV-DP). TFV-DP este metabolitul activ. Din punct de vedere structural, este un analog al deoxiadenozin-5\u2032-trifosfatului (dATP).<\/p>\n<p>Polimeraza HBV \u0219i transcriptaza invers\u0103 a HIV confund\u0103 TFV-DP cu dATP \u0219i \u00eel \u00eencorporeaz\u0103 \u00een lan\u021bul de ADN viral \u00een cre\u0219tere. Odat\u0103 \u00eencorporat, absenta grupului 3\u2032-hidroxil previne ad\u0103ugarea urm\u0103torului nucleotide \u2014 lan\u021bul se termin\u0103. F\u0103r\u0103 ADN viral complet, nu se asambleaz\u0103 noi virioni infec\u021bio\u0219i.<\/p>\n<p>Timpul de \u00eenjum\u0103t\u0103\u021bire intracelular al TFV-DP dep\u0103\u0219e\u0219te 50 de ore, motiv pentru care dozarea o dat\u0103 pe zi men\u021bine suprimarea viral\u0103 continu\u0103 \u0219i de ce medicamentul r\u0103m\u00e2ne activ c\u00e2teva zile dup\u0103 o doz\u0103 ratat\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Dosage and How to Take Teravir<\/h2>\n<table style=\"border-collapse:collapse;width:100%;font-size:14px;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Indica\u021bie<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Doza standard pentru adul\u021bi<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Durata tratamentului<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Hepatit\u0103 B cronic\u0103<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">300 mg o dat\u0103 pe zi cu m\u00e2ncare<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Pe termen lung \u2014 de obicei nedeterminat. \u00centreruperea necesit\u0103 supraveghere specializat\u0103 (risc de reactivare).<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">HIV (combina\u021bie)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">300 mg o dat\u0103 pe zi cu m\u00e2ncare<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Pe termen nelimitat, ca parte a unui regim terapeutic combinat.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">PrEP \/ PEP (combina\u021bie)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">300 mg + FTC 200 mg o dat\u0103 pe zi<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">PrEP zilnic\u0103 \u00een timp ce persista riscul; PEP timp de 28 de zile.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Lua\u021bi cu m\u00e2ncare<\/strong> \u2014 cre\u0219te biodisponibilitatea cu aproximativ 40%. \u00cenghi\u021bi\u021bi comprimatul \u00eentreg cu ap\u0103; nu-l desp\u0103r\u021bi\u021bi sau zdrobi\u021bi. Dac\u0103 uita\u021bi o doz\u0103 cu mai pu\u021bin de 12 ore, lua\u021bi-o c\u00e2t mai cur\u00e2nd posibil; dac\u0103 au trecut mai mult de 12 ore, omite\u021bi doza ratat\u0103 \u0219i relua\u021bi urm\u0103toarea doz\u0103 conform programului. Nu lua\u021bi o doz\u0103 dubl\u0103.<\/p>\n<p><strong>Ajustarea dozei la insuficien\u021b\u0103 renal\u0103 (indica\u021bie VHB):<\/strong><\/p>\n<ul>\n<li>ClCr \u2265 50 ml\/min \u2014 300 mg la fiecare 24 de ore (f\u0103r\u0103 modificare)<\/li>\n<li>ClCr 30\u201349 ml\/min \u2014 300 mg la fiecare 48 de ore<\/li>\n<li>ClCr 10\u201329 ml\/min \u2014 300 mg la fiecare 72\u201396 de ore<\/li>\n<li>Hemodializ\u0103 \u2014 300 mg la fiecare 7 zile, dup\u0103 dializ\u0103 \u00een zilele de dializ\u0103<\/li>\n<\/ul>\n<p>Pentru func\u021bia renal\u0103 \u00een deteriorare la pacien\u021bii trata\u021bi cu TDF, trecerea la <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\" rel=\"noopener\">tenofovir alafenamid (TAF)<\/a> \u2014 acela\u0219i principiu activ, expunere renal\u0103 \u0219i osoas\u0103 redus\u0103 \u2014 este preferat\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente (\u2265 1 din 100 de pacien\u021bi):<\/strong> gre\u021buri, diaree, cefalee, oboseal\u0103, erup\u021bii cutanate u\u0219oare, ame\u021beli, hipofosfatemie (adesea asimptomatice, depistate \u00een analizele de s\u00e2nge).<\/p>\n<p><strong>Pu\u021bin frecvente p\u00e2n\u0103 rare, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Toxicitate renal\u0103<\/strong> \u2014 sc\u0103dere mic\u0103, \u00een mare parte reversibil\u0103 a eGFR este frecvent\u0103. Tubulopatia proximal\u0103 \u0219i sindromul Fanconi (proteinurie, glicozurie cu glicemie normal\u0103, pierdere de fosfat, dureri osoase) sunt neobi\u0219nuite dar pot fi grave. Monitoriza\u021bi eGFR, proteinuria, fosfatemia la ini\u021biere, apoi la fiecare 3\u20136 luni.<\/li>\n<li><strong>Pierdere de densitate mineral\u0103 osoas\u0103<\/strong> \u2014 reducere mic\u0103 a DMO \u00een primul an, apoi se stabilizeaz\u0103. Relevante clinic la pacien\u021bii cu osteoporoz\u0103 preexistent\u0103 sau istoric de fracturi de fragilitate.<\/li>\n<li><strong>Acidoz\u0103 lactic\u0103 cu hepatomegalie sever\u0103 \u2014 efect de clas\u0103 rar al NRTI-urilor.<\/strong> \u00centrerupe\u021bi imediat tratamentul dac\u0103 apar dureri abdominale progresive neexplicate, respira\u021bie rapid\u0103, oboseal\u0103 sever\u0103 sau dureri musculare.<\/li>\n<li><strong>Exacerbare acut\u0103 sever\u0103 de hepatit\u0103 B<\/strong> \u2014 poate ap\u0103rea la \u00eentreruperea TDF, chiar dup\u0103 ani de suprimare. Necesit\u0103 monitorizarea enzimelor hepatice \u0219i ADN-ului HBV timp de cel pu\u021bin 6 luni dup\u0103 \u00eentrerupere.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<p>Tenofovirul are pu\u021bine interac\u021biuni cu citocromul-P450, dar mai multe interac\u021biuni farmacocinetice semnificative clinic:<\/p>\n<ul>\n<li><strong>Didanosine (ddI)<\/strong> \u2014 tenofovir cre\u0219te nivelurile de ddI; risc de pancreatit\u0103. Combina\u021bia este de obicei evitat\u0103.<\/li>\n<li><strong>Atazanavir (neboostat)<\/strong> \u2014 tenofovir scade nivelurile de atazanavir. Atazanavirul trebuie s\u0103 fie boostat cu ritonavir atunci c\u00e2nd este administrat cu TDF.<\/li>\n<li><strong>Alte medicamente nefrototoxice<\/strong> \u2014 aminoglicozidele concomitente, AINS-uri \u00een doze mari (\u00een special diclofenac sau ibuprofen pe termen lung), cidofovir, foscarnet, vancomicin\u0103 IV, amfotericin\u0103 B IV, cisplatina cresc riscul de leziuni renale.<\/li>\n<li><strong>Adefovir<\/strong> \u2014 nu combina\u021bi cu TDF; ambele apar\u021bin clasei tenofovir. Acela\u0219i metabolit activ.<\/li>\n<li><strong>Probenecid, ledipasvir, ranitidin\u0103<\/strong> \u2014 cresc expunerea la tenofovir; de obicei \u00eenc\u0103 sigur, dar monitoriza\u021bi func\u021bia renal\u0103.<\/li>\n<\/ul>\n<p><strong>Not\u0103 privind coinfec\u021bia cu hepatita C:<\/strong> regimuri DAA pe baz\u0103 de sofosbuvir (inclusiv <a href=\"https:\/\/medsbase.com\/ro\/hepcinat-lp\/\" rel=\"noopener\">Hepcinat LP<\/a>) sunt sigure cu TDF, dar ledipasvir cre\u0219te u\u0219or expunerea la tenofovir \u2014 verifica\u021bi eGFR mai frecvent \u00een timpul cursului DAA de 12 s\u0103pt\u0103m\u00e2ni.<\/p>\n<h2 class=\"wp-block-heading\">Who Should Not Take Teravir?<\/h2>\n<ul>\n<li>Insuficien\u021b\u0103 renal\u0103 sever\u0103 (CrCl &lt; 10 mL\/min) f\u0103r\u0103 ajustare de doz\u0103 sau acces la dializ\u0103<\/li>\n<li>Hipersensibilitate cunoscut\u0103 la tenofovir disoproxil<\/li>\n<li>Tratament concomitent cu adefovir sau didanozin\u0103 f\u0103r\u0103 supraveghere specializat\u0103<\/li>\n<li>Ciroz\u0103 decompensat\u0103 \u2014 specialistul ar trebui s\u0103 evalueze entecavir vs TDF; ambele sunt op\u021biuni.<\/li>\n<\/ul>\n<p>Sarcin\u0103: tenofovir disoproxil are cele mai solide date de siguran\u021b\u0103 \u00een sarcin\u0103 \u0219i al\u0103ptare dintre toate agen\u021bii orali pentru HBV\/HIV \u2014 preferat \u00een sarcin\u0103 c\u00e2nd este nevoie de tratament (de ex. mam\u0103 cu \u00eenc\u0103rc\u0103tur\u0103 viral\u0103 ridicat\u0103 pentru a preveni transmiterea vertical\u0103 a HBV \u00eencep\u00e2nd cu s\u0103pt\u0103m\u00e2na 28).<\/p>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi la temperatura camerei, sub 30\u00b0C, \u00een flaconul original cu desiccant. Depozita\u021bi \u00een afara accesului copiilor. Nu transfera\u021bi \u00een organizatoare de pastile s\u0103pt\u0103m\u00e2nale pentru perioade lungi \u2014 desiccantul conteaz\u0103.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Is Teravir the same as Viread?<\/h3>\n<p>Yes &mdash; same molecule, same strength, same indication. Viread is the originator (Gilead). Teravir is a Cipla generic of the same tenofovir disoproxil fumarate 300 mg formulation. Bioequivalence studies are required to register the generic in regulated markets.<\/p>\n<h3 class=\"wp-block-heading\">Will Teravir cure my hepatitis B?<\/h3>\n<p>Nu. Tenofovir suprim\u0103 replicarea HBV at\u00e2t de eficient \u00eenc\u00e2t ADN-ul viral devine de obicei nedetectabil, ALT se normalizeaz\u0103, iar progresia spre ciroz\u0103 sau carcinom hepatocelular \u00eencetine\u0219te semnificativ. Dar rezervorul de cccDNA din hepatocitele infectate nu este eliminat \u2014 \u00eentreruperea medicamentului permite reluarea replic\u0103rii. Vindecarea func\u021bional\u0103 (pierdere HBsAg) apare \u00een aproximativ 1\u20133% pe an de tratament; vindecarea steril\u0103 este \u00een prezent imposibil\u0103. Tratamentul este, prin urmare, pe termen lung \u2014 \u00een multe cazuri pe via\u021b\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Can I use Teravir alone for HIV?<\/h3>\n<p>No. Tenofovir monotherapy for established HIV-1 infection causes rapid resistance. HIV requires a minimum of three active drugs from at least two different classes. Teravir is one component of that regimen, never the whole thing.<\/p>\n<h3 class=\"wp-block-heading\">How long does it take for Teravir to work?<\/h3>\n<p>ADN-ul HBV \u00eencepe de obicei s\u0103 scad\u0103 \u00een 4 s\u0103pt\u0103m\u00e2ni. La 6 luni, 70\u201380% ating \u00eenc\u0103rc\u0103tur\u0103 viral\u0103 nedetectabil\u0103; la 5 ani, &gt; 90%. Normalizarea ALT urmeaz\u0103 de obicei suprima\u021bia ADN-ului \u00een 3\u20136 luni. Seroconversia HBeAg (un marker de vindecare par\u021bial\u0103) apare la aproximativ 20\u201330% din pacien\u021bii HBeAg-pozitivi pe parcursul a 5 ani.<\/p>\n<h3 class=\"wp-block-heading\">De ce este at\u00e2t de important monitorizarea renal\u0103?<\/h3>\n<p>TDF se concentreaz\u0103 \u00een tubulii renali proximali. Noul formulat alafenamid (TAF) a fost conceput special pentru a reduce expunerea tubular\u0103 \u2014 acela\u0219i principiu activ, dar nivelurile plasmatice sunt cu 90% mai mici. Majoritatea sc\u0103derilor renale legate de TDF sunt mici \u0219i reversibile dac\u0103 sunt depistate devreme; scopul monitoriz\u0103rii trimestriale a eGFR \u0219i fosfatului seric este de a identifica cazurile rare progresive \u00eenainte de apari\u021bia leziunilor structurale.<\/p>\n<h3 class=\"wp-block-heading\">Teravir vs TAF (tenofovir alafenamide) &mdash; which should I take?<\/h3>\n<p>Ambele furnizeaz\u0103 tenofovir hepatocitelor (HBV) \u0219i limfocitelor (HIV). TAF atinge niveluri intracelulare mai mari la expunere plasmatic\u0103 mult mai mic\u0103, ceea ce reduce toxicitatea renal\u0103 \u0219i osoas\u0103. TAF este preferat dac\u0103 ave\u021bi BRC stadial 2\u20133, osteoporoz\u0103 sau sunte\u021bi peste 60 de ani. TDF (acest produs) are o baz\u0103 de date de siguran\u021b\u0103 de 20 de ani, cost\u0103 mai pu\u021bin \u0219i poate fi u\u0219or preferat \u00een sarcin\u0103, unde datele despre TAF sunt \u00eenc\u0103 \u00een curs de acumulare. Discuta\u021bi cu hepatologul sau medicul dumneavoastr\u0103 de HIV despre schimbare dac\u0103 ave\u021bi orice toxicitate legat\u0103 de TDF.<\/p>\n<h3 class=\"wp-block-heading\">Can I drink alcohol on Teravir?<\/h3>\n<p>Alcoolul nu interac\u021bioneaz\u0103 direct cu tenofovirul, dar consumul excesiv accelereaz\u0103 deteriorarea hepatic\u0103 la HBV cronic. Limita\u021bi alcoolul la consum moderat sau abstine\u021bi complet dac\u0103 ave\u021bi fibroz\u0103 sau ciroz\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Can I stop Teravir once my HBV DNA is undetectable?<\/h3>\n<p>\u00cen general, nu. \u00centreruperea declan\u0219eaz\u0103 revenirea viral\u0103 la &gt; 90% din pacien\u021bi \u00een 3 luni, iar o minoritate experimenteaz\u0103 puseuri acute severe cu risc de decompensare hepatic\u0103. \u00centreruperea este luat\u0103 \u00een considerare doar dup\u0103 pierderea HBsAg cu seroconversie anti-HBs (vindecare func\u021bional\u0103), \u0219i chiar \u0219i atunci sub supraveghere specializat\u0103 cu monitorizare frecvent\u0103 timp de 6\u201312 luni.<\/p>\n<h3 class=\"wp-block-heading\">Does Teravir prevent mother-to-child transmission of HBV?<\/h3>\n<p>Da \u2014 la mamele cu viremie ridicat\u0103 (ADN HBV &gt; 200.000 UI\/mL), administrarea tenofovir disoproxil \u00eencep\u00e2nd cu s\u0103pt\u0103m\u00e2na 28 de sarcin\u0103 \u0219i continu\u00e2nd \u00een perioada postnatal\u0103 timpurie reduce transmiterea vertical\u0103 aproape la zero atunci c\u00e2nd este combinat\u0103 cu imunizarea activ\u0103 \u0219i pasiv\u0103 a nou-n\u0103scutului. Aceasta este o indica\u021bie recunoscut\u0103 \u00een ghidurile WHO, EASL \u0219i AASLD.<\/p>\n<h3 class=\"wp-block-heading\">Where can I order Teravir?<\/h3>\n<p>You can order Teravir directly from MedsBase. We supply genuine Cipla stock with worldwide shipping. We strongly recommend treatment under the supervision of a hepatologist or infectious-diseases specialist for HBV monitoring (LFTs, HBV DNA, fibroscan) and renal monitoring while on therapy.<\/p>\n<h2 class=\"wp-block-heading\">Declinare de responsabilitate<\/h2>\n<p>Informa\u021biile de pe aceast\u0103 pagin\u0103 au scop educa\u021bional \u0219i nu \u00eenlocuiesc sfatul medical profesionist. Tratamentul hepatitei cronice B \u0219i HIV necesit\u0103 evaluare ini\u021bial\u0103, monitorizare continu\u0103 \u0219i supraveghere specializat\u0103. Nu \u00eencepe\u021bi, \u00eentrerupe\u021bi sau modifica\u021bi terapia pe baz\u0103 de tenofovir f\u0103r\u0103 a consulta un clinician calificat.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Pacien\u021bii care iau <a href=\"https:\/\/medsbase.com\/ro\/teravir\/\">Teravir<\/a> (tenofovir disoproxil fumarate 300&nbsp;mg) for hepatitis B who also require HIV pre-exposure prophylaxis can consider <a href=\"https:\/\/medsbase.com\/ro\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarat 300 mg + emtricitabin\u0103 200 mg)<\/a>, which adds the emtricitabine co-formulation required for approved dual-component PrEP efficacy.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/betapro-sr\/\">Betapro-SR<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/simlo-5\/\">Simlo 5<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/topaz\/\">Topaz<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/budecort-rotacaps\/\">Budecort Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/nucoxia-sp\/\">Nucoxia SP<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Suppresses HIV replication<br \/>\n\u2705 Reduce \u00eenc\u0103rc\u0103tura viral\u0103<br \/>\n\u2705 Boosts immune function<br \/>\n\u2705 Delays disease progression<br \/>\n\u2705 Prevents opportunistic infections<\/p>\n<p>Teravir contains Tenofovir.<\/p>","protected":false},"featured_media":60764,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334,3304],"product_tag":[3335,4917],"class_list":{"0":"post-60763","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_cat-hiv-medication","10":"product_tag-tenofovir","11":"product_tag-teravir","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60763"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60764"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60763"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60763"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60763"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}